-
PDF
DOCUMENT
New pediatric dosing
information for Kaletra, patients 14 days to 6 months and 12-18 years of
age
and update information on coadministration with midazolam ,
US FDA June 23, 2008 -
CONFERENCE PDF
POSTER
Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN
trial
A Hill, A-G Marcelin, V Calvez, et al 2008 International
HIV Drug Resistance Workshop-
Safety of Long-term Lopinavir Plasma-levels in Patients with Liver Disease.
Langmann P, Hubert C, Heinz W, et al Eur J Med Res. 2008 May
26;13(5):205-8. -
Enzymatic and Structural Analysis of the I47A Mutation Contributing to the
Reduced Susceptibility to HIV Protease
Inhibitor Lopinavir.
Grantz Saskova K, Kozisek M, et al Protein Sci.
2008 Jun 17. -
A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by
Lopinavir-Ritonavir Monotherapy versus
Efavirenz Combination Therapy.
Cameron DW, da Silva BA, Arribas JR, et al J
Infect Dis. 2008 Jun 9.
-
Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or
Without Cirrhosis.
Micheli V, Regazzi M, Dickinson L,
et al Ther
Drug Monit. 2008 Jun;30(3):306-313
|
|
|
|
|
New
and Noteworthy
Guidelines
Journal Papers/Abstracts/
Commentaries